v3.26.1
Condensed Consolidated Statements of Stockholders’ Deficit - USD ($)
$ in Thousands
Total
Pre-Funded Warrant
Series 1 Warrants
Series 2 Warrants
Common Stock
Additional Paid-in Capital
Additional Paid-in Capital
Pre-Funded Warrant
Additional Paid-in Capital
Series 1 Warrants
Additional Paid-in Capital
Series 2 Warrants
Accumulated Other Comprehensive Gain (Loss)
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2024         55,594,131            
Beginning balance at Dec. 31, 2024 $ (45,528)       $ 6 $ 512,515       $ 135 $ (558,184)
Increase (Decrease) in Stockholders' Equity                      
Issuance of common stock upon exercise of stock options and employee stock purchase plan (in shares)         127,209            
Issuance of common stock upon exercise of stock options and employee stock purchase plan 139         139          
Stock-based compensation expense 2,692         2,692          
Unrealized losses on marketable securities (121)                 (121)  
Net loss (18,834)                   (18,834)
Ending balance (in shares) at Mar. 31, 2025         55,721,340            
Ending balance at Mar. 31, 2025 (61,652)       $ 6 515,346       14 (577,018)
Beginning balance (in shares) at Dec. 31, 2024         55,594,131            
Beginning balance at Dec. 31, 2024 (45,528)       $ 6 512,515       135 (558,184)
Increase (Decrease) in Stockholders' Equity                      
Unrealized losses on marketable securities (179)                    
Net loss (36,770)                    
Ending balance (in shares) at Jun. 30, 2025         55,803,195            
Ending balance at Jun. 30, 2025 (76,659)       $ 6 518,333       (44) (594,954)
Beginning balance (in shares) at Mar. 31, 2025         55,721,340            
Beginning balance at Mar. 31, 2025 (61,652)       $ 6 515,346       14 (577,018)
Increase (Decrease) in Stockholders' Equity                      
Issuance of common stock upon exercise of stock options and employee stock purchase plan (in shares)         81,855            
Issuance of common stock upon exercise of stock options and employee stock purchase plan 254         254          
Stock-based compensation expense 2,733         2,733          
Unrealized losses on marketable securities (58)                 (58)  
Net loss (17,936)                   (17,936)
Ending balance (in shares) at Jun. 30, 2025         55,803,195            
Ending balance at Jun. 30, 2025 $ (76,659)       $ 6 518,333       (44) (594,954)
Beginning balance (in shares) at Dec. 31, 2025 56,657,329       56,657,329            
Beginning balance at Dec. 31, 2025 $ (108,500)       $ 6 523,937       24 (632,467)
Increase (Decrease) in Stockholders' Equity                      
Issuance of common stock from direct offering, net of offering costs (in shares)         2,030,314            
Issuance of common stock from direct offering, net of offering costs 10,213         10,213          
Issuance of pre-funded warrants from direct offering, net of offering costs   $ 27,271 $ 2,942 $ 9,226     $ 27,271 $ 2,942 $ 9,226    
Issuance of common stock upon exercise of stock options and employee stock purchase plan (in shares)         22,847            
Issuance of common stock upon exercise of stock options and employee stock purchase plan 89         89          
Stock-based compensation expense 2,383         2,383          
Unrealized losses on marketable securities (157)                 (157)  
Net loss (19,875)                   (19,875)
Ending balance (in shares) at Mar. 31, 2026         58,710,490            
Ending balance at Mar. 31, 2026 $ (76,408)       $ 6 576,061       (133) (652,342)
Beginning balance (in shares) at Dec. 31, 2025 56,657,329       56,657,329            
Beginning balance at Dec. 31, 2025 $ (108,500)       $ 6 523,937       24 (632,467)
Increase (Decrease) in Stockholders' Equity                      
Unrealized losses on marketable securities (158)                    
Net loss $ (27,066)                    
Ending balance (in shares) at Jun. 30, 2026 58,714,272       58,714,272            
Ending balance at Jun. 30, 2026 $ (81,041)       $ 6 578,620       (134) (659,533)
Beginning balance (in shares) at Mar. 31, 2026         58,710,490            
Beginning balance at Mar. 31, 2026 (76,408)       $ 6 576,061       (133) (652,342)
Increase (Decrease) in Stockholders' Equity                      
Issuance of common stock upon exercise of stock options and employee stock purchase plan (in shares)         3,782            
Issuance of common stock upon exercise of stock options and employee stock purchase plan 9         9          
Stock-based compensation expense 2,550         2,550          
Unrealized losses on marketable securities (1)                 (1)  
Net loss $ (7,191)                   (7,191)
Ending balance (in shares) at Jun. 30, 2026 58,714,272       58,714,272            
Ending balance at Jun. 30, 2026 $ (81,041)       $ 6 $ 578,620       $ (134) $ (659,533)